Vaccination in pediatric acquired inflammatory immune-mediated neuromuscular disorders.
Bell's palsy
Chronic inflammatory demyelinating polyneuropathy
Guillain-barré syndrome
Immune-mediated inflammatory myopathy
Immunosupressive treatment
Myasthenia gravis
Optic neuritis
Pediatric immune-mediated inflammatory neuromuscular disorders
Vaccination
Vaccine safety
Vaccines
Journal
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
ISSN: 1532-2130
Titre abrégé: Eur J Paediatr Neurol
Pays: England
ID NLM: 9715169
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
24
09
2020
revised:
15
11
2021
accepted:
18
12
2021
pubmed:
9
1
2022
medline:
19
1
2022
entrez:
8
1
2022
Statut:
ppublish
Résumé
To analyse literature data on vaccine related induction, worsening of the disease and disease reccurrences as well as vaccine safety and efficacy among pediatric patients with acquired inflammatory immune-mediated neuromuscular disorders (NMD). Medline, Pub Med and Scopus database search from 1975 to 2020 focused on pediatric age was conducted including peer reviews, meta analyses and epidemiological studies on vaccination and Guillain-Barré syndrome (GBS), Bell's palsy, optic neuritis (ON), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and immune-mediated inflammatory myopathy (IM). s: There are no strong evidence supporting relationship between vaccination with different pediatric vaccines and development of first episodes or reccurrences of GBS, Bell's palsy, optic neuritis (ON), juvenile MG, CIDP, and IM. The vaccination and revaccination with inactivated vaccines is considered safe in children with medical history of GBS, Bell's palsy, ON, MG and IM. Caution when immunization against influenza, quadrivalent conjugated meningococcal vaccine (MCV4) and pneumococcal disease and avoiding tetanus toxoid immunization in CIDP patients is suggested. Patients with immune mediated acquired NMD should be vaccinated with live vaccines before the initiation of immunosupressive treatment. Immunosuppressed patients with low protective antibody titers should be considered for revaccination.
Identifiants
pubmed: 34998097
pii: S1090-3798(21)00234-8
doi: 10.1016/j.ejpn.2021.12.014
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-176Informations de copyright
Copyright © 2021 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.